A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT01843790
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- La Jolla Pharmaceutical Company
- Registry
-
NCT01843790
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01843790. Randomized; single masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- GCS-100
- Intervention (Drug)
- Placebo, Saline
- Lead sponsor
- La Jolla Pharmaceutical Company
Record details
- Record id
cardio:ct-nct01843790- Content hash
836780159c7bb9c2f3cc3b655e994ac090a12658dc702ee4b9e9c25af87cdf61